



curasan
Regenerative Medicine

Osbone® – the safe
alternative for
happy patients



Dear Dentist,


Developing an effective solution for happy patients while maintaining respect for patient safety, is the foundation of all curasan products. **Osbone®** is a synthetic, open-cell cancellous bone replacement material for filling bone defects. It is the alternative to hydroxyapatites of allogeneic or xenogeneic origin and eliminates the risk of infections and allergic reactions. As a synthetic manufactured material **Osbone®** provides you with a consistent level of quality.

Learn more about the use, application and added value of this innovative and safe treatment option.

Still have questions?
Your sales representative will be happy to assist you.

curasan AG

Osbone®



What is Osborne®?

Osbone® – synthetic bone replacement material


- + eliminates the risk of allergic reactions and infections
- + hydroxyapatite
- + high degree of purity and consistent quality

For use in dental medicine, implantology, periodontology as well as oral and maxillofacial surgery.



Osbone® – improving patient safety. Eliminates infection and allergy risks.

What is Osborne®?



„The safety and predictability of the treatment are top priorities. This is why Osborne®, as a synthetic hydroxyapatite for bone augmentation, has been my treatment of first choice for many years.“


Dr. Kay Pehrsson, dentist at the Haranni Clinic, Herne, Germany

Why Osborne®?



Osbone® – the compelling alternative

- + eliminates the risk of infections and allergies.
- + increases patient confidence with a synthetic alternative to allografts or xenografts.
- + simplifies informed consent obligations.




Osbone® – for improved patient safety. Eliminates infection and allergy risks.

Indications

Osbone®

„The new bone replacement material Osbone® is particularly suitable for use in indications that call for increased mechanical stability, because it offers the best possible structures for osseointegration and is characterised by low absorption kinetics and excellent biocompatibility.“¹


Complete osseointegration of Osbone® for a stable and functional implant bed.



Osbone® for filling defects and bone augmentation

- + for an optimal osteoconductive scaffold
- + for long-lasting volume stability
- + for large-volume augmentations

Application



picture credits: Prof. NYU Dr. Ady Palti, Baden-Baden

Best practice sinus lift surgery


- 1 Prepared, exposed defect
- 2 Insertion of the bioabsorbable collagen membrane Osgide®
- 3 Loose filling of the defect
- 4 Closure of the bone window with membrane
- 5 Saliva-proof wound closure

Osbone® – improving patient safety. Eliminates infection and allergy risks.


Results

Osbone®

„It was demonstrated that the specific ALP activity of the cells increases throughout the entire cultivation period. The studied material Osbone® is thus able to support not only the adhesion and proliferation, but also the osteogenic differentiation of human osteoblasts.“²




Osbone® after 1 day of cell culture




Osbone® after 28 days of cell culture

Osbone® and bovine hydroxyapatite in comparison:



Good cell colonisation of Osbone®


picture credits: Dr. Kay Peirsson, Herne



Isolated cell formation on bovine hydroxyapatite


Clinical experience

In a prospective, multicentre trial³ with 190 patients, **Osbone®** was found to have excellent biocompatibility and osseointegration with low absorption kinetics. It is particularly suitable for use in indications that call for increased mechanical stability.



External sinus lift.
Complete filling of the defect with **Osbone®**

picture credits: Dr. Kay Pehrsson, Herne



Six months post-operatively, prior to re-entry and final treatment: good osseointegration of the implants (residual granules visible at site 26).

Osbone® – the safe
alternative for
satisfied patients.

Product offer

Osbone®

„Compared to other hydroxyapatite materials, Osbone® is preferable especially because of the synthetic manufacture.“⁴


Osbone® product properties

- + synthetic
- + phase purity ($\geq 95\%$)
- + polygonally shaped granules
- + open-cell porous



Osbone®	Grain size	Content	Item number	Item no. mds
Grain size small	250-1000 μm	5 x 0,25 cc	9000800255	88400
	250-1000 μm	1 x 0,5 cc	9000800501	88401
	250-1000 μm	5 x 0,5 cc	9000800505	88402
	250-1000 μm	1 x 1 cc	9000801001	88403
	250-1000 μm	5 x 1 cc	9000801005	88404

Osbone®	Grain size	Content	Item number	Item no. mds
Grain size large	1000-2000 μm	1 x 1 cc	9000901001	88405
	1000-2000 μm	5 x 1 cc	9000901005	88406
	1000-2000 μm	1 x 2 cc	9000902001	88407



References

^{1,3} **Holweg A, Lerner H, Pehrsson K (2012):**
Synthetisches Hydroxylapatit in der Dental-Chirurgie. (Ergebnisse einer offenen prospektiven multizentrischen Studie mit 190 Patienten).
teamwork J Cont Dent Educ 2012, 5, 419-425.

² **Peters F, Bernhardt A, Lode A, Gelinsky M (2010):**
Osbone® eine neue, synthetische Biokeramik für den Knochenersatz.
Regen. Med. 2010; 3 (1): 18-22.

⁴ **Keller U (2011):**
Implantation mit simultaner vestibulärer Alveolarkammaugmentation.
ZMK Juli/August 2011, Sonderausgabe: 27: 26-29.

Ludwig A (2011):

Knochenaufbau- und Regeneration mit einem synthetischen Hydroxylapatit. Implantologie Journal 2011; 8: 28-33.

„No material-related inflammatory reactions were seen in the observed clinical courses. All in all, it appears as though the good in-vitro cell colonisation properties (Bernhardt et al. 2011) are also confirmed in the clinical course.“

Bernhardt A, Lode A, Peters F, Gelinsky M (2011):

Novel ceramic bone replacement material Osbone® in a comparative in vitro study with osteoblasts. Clin Oral Implants Res. 2011 Jun; 22 (6): 651-657. doi: 10.1111/j.1600-0501.2010.02015.x. Epub 2010 Oct 6.

„The Osbone® granules support the proliferation and osteogenic differentiation of osteoblasts in-vitro and are thus promising candidates for in-vivo applications.“

Osbone® – improving
patient safety.
Eliminates infection
and allergy risks.

Publisher:

curasan
Regenerative Medicine

curasan AG
Lindigstraße 4
63801 Kleinostheim
Germany

T +49 (0) 6027 40900-0
F +49 (0) 6027 40900-49
www.curasan.com